NX Development Corp
Phoenix, Arizona
What changed
Phase III trial registered: Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma
2mo agoTrial registeredMay 18, 2026Source filing (opens the source filing in a new tab)
Momentum
Momentum 76 out of 100, unchanged since the last recompute.
Accelerating: several high-weight events landed recently.
Runway (estimate)
No disclosed raise on file, so there is nothing to model from.
Stage
Phase III
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
- Trial
PHASE1 registered
Jan 27, 2025Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO), Glioblastoma (GBM) · COMPLETED · sponsor: Universität Münster · Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)
ClinicalTrials.gov · NCT06665724 (opens the source filing in a new tab)
- Trial
PHASE3 registered
Oct 28, 2020Meningioma · COMPLETED · sponsor: NX Development Corp · Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma
ClinicalTrials.gov · NCT04305470 (opens the source filing in a new tab)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources